Laverock Therapeutics, a gene control company powering the development of disease-responsive advanced therapies, announces the expansion of its seed funding round, taking the total raised to more than £20m. The investment was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and Maven Capital Partners. The company also welcomed new investor, Norcliffe Capital.
This additional investment marks a transformational period for Laverock. The company has achieved platform development and validation and is transitioning to lead product selection, reporting positive functional data for both its primary T-cell and Macrophage programmes, demonstrating enhanced tumour control in haematological and solid tumour cancer models. Laverock’s unique platform technologies provide the potential to transform the efficacy, precision and safety of advanced therapies, through implementation of its programmable, tunable and multiplex gene silencing approach.
To reflect Laverock’s recent progress, the company has updated its corporate identity, including the launch of a new website, to demonstrate the expansion of its platform technologies and facilitate an enhanced focus on partnering and outlicensing activities.
